Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial - PubMed
11 hours ago
- #beta-blocker
- #hypertrophic cardiomyopathy
- #calcium-channel blocker
- The study compared the effects of bisoprolol (beta-blocker) and verapamil (calcium-channel blocker) in nonobstructive hypertrophic cardiomyopathy (HCM) using a randomized, double-blinded, placebo-controlled triple-crossover trial.
- Primary outcome was peak oxygen consumption (pVO2), which was significantly lower with bisoprolol compared to verapamil and placebo. Verapamil showed no significant difference in pVO2 compared to placebo.
- Bisoprolol reduced peak heart rate more than verapamil and negatively impacted symptoms, biomarkers, and structural parameters, whereas verapamil improved global longitudinal strain and reduced NT-proBNP levels.
- Neither drug changed oxygen consumption at anaerobic threshold or the minute ventilation/CO2 production slope. NYHA functional classification remained unchanged with both treatments.
- The study provides new insights into the mechanisms of these drugs, suggesting potential considerations for managing nonobstructive HCM.